--- title: "Novo Nordisk's 27% profit jump is the adjusted number; the reported number fell 9%" description: "Novo's beat-and-raise quarter hides a flat underlying US market propped up by a temporary Medicare bridge, and a reported profit that fell 9% while the adjusted line rose 27%. The CFO who called the write-offs one-offs leaves on December 31." publisher: "The Inference" section: "Health" published: 2026-11-05T16:34:44.895Z modified: 2026-11-05T16:34:44.895Z canonical: https://theinference.org/article/novo-nordisk-s-27-profit-jump-is-the-adjusted-number-the-reported-number-fell-9 language: en keywords: "Earnings, Novo Nordisk, Wegovy, Obesity, Pharma" --- # Novo Nordisk's 27% profit jump is the adjusted number; the reported number fell 9% > Novo's beat-and-raise quarter hides a flat underlying US market propped up by a temporary Medicare bridge, and a reported profit that fell 9% while the adjusted line rose 27%. The CFO who called the write-offs one-offs leaves on December 31. [Novo Nordisk](https://theinference.org/markets/companies/novo-nordisk)'s stock jumped more than 6% on November 4 after the Danish drugmaker beat expectations and [raised its 2026 guidance](https://www.indianpharmapost.com/news/novo-nordisk-raises-2026-outlook-after-stronger-than-expected-q3-driven-by-obesity-drug-sales-22330) [1][3][5]. Adjusted sales rose 4% to DKK 79.2 billion ($11.9 billion) and adjusted operating profit climbed 27% at constant exchange rates to about DKK 32 billion [1][3][5]. The Wegovy pill ["exceeded our expectations,"](https://finance.yahoo.com/healthcare/articles/novo-nordisk-nvo-q3-2026-190719869.html) CEO Mike Doustdar said, with [more than 8 million cumulative prescriptions](https://theinference.org/article/novo-s-wegovy-pill-inherits-a-32-billion-franchise-as-a-judge-declines-to-block-lilly-s-ads) since its January launch [1][3][5]. That is the headline. Underneath it sit two disclosures that change how the quarter should be priced. [1][3][5] ## One quarter, two profit numbers The 27% jump is the adjusted line [2][3]. The reported line fell 9% at constant exchange rates, [dragged down by DKK 8.7 billion in non-cash impairment charges](https://www.fiercebiotech.com/biotech/novos-ceo-still-looking-deals-close-some-gaps-misfires-hit-profits): DKK 4.6 billion from killing the cardiovascular drug ziltivekimab, DKK 4.1 billion from right-sizing the manufacturing network, plus, per Fierce Biotech, DKK 4.0 billion for scrapping the obesity candidate monlunabant, out of DKK 15 billion in major charges. [2][3] CFO Karsten Munk Knudsen called them one-offs that leave "a much cleaner balance sheet." He leaves the company on December 31 after 27 years, [replaced by Luigi La Corte of Galderma](https://finance.yahoo.com/healthcare/articles/novo-hires-cfo-wegovy-pill-191832757.html) [3][4]. The man signing the quarter is the man leaving it. [3][4] *Chart: **Novo's Q3: adjusted profit up 27%, reported profit down 9%** Columns comparing Novo Nordisk Q3 2026 growth rates: adjusted operating profit +27%, adjusted sales +4%, US operations sales +1%, and reported operating profit -9%* *Year-over-year growth at constant exchange rates, Q3 2026. Reported operating profit falls 9% on DKK 8.7 billion of impairments; adjusted operating profit rises 27% against a DKK 9 billion charge base in Q3 2025. Sources: GuruFocus via Yahoo Finance; Indian Pharma Post. [1][2]* ## The growth runs through a bridge that ends US operations grew just 1% [1]. The engine was the Medicare bridge program, running at roughly 60,000 prescriptions a week, which drove Wegovy's 20% sequential volume rise "largely but not exclusively," per US chief Jamey Millar [1]. Excluding it, the obesity category was relatively flat from May to October. Guidance sits at zero growth for 2026, and [Wegovy's US price erosion ran 30-35%](https://theinference.org/article/novo-nordisk-halves-wegovy-s-us-price-to-675-and-lifts-2026-guidance-for-the-third-time) in the quarter. [1] 2027 therefore leans on CagriSema, [whose FDA decision is due before year-end](https://www.biospace.com/business/novo-lilly-battle-for-oral-glp-1-dominance-with-data-tit-for-tat), and on deals: Doustdar is hunting acquisitions to "close some of the gaps" his write-offs just priced [3][5]. The new CFO inherits the zero-growth guide and the shopping list. Watch the CagriSema decision. [3][5] ## Takeaway Judge Novo's quarter on the reported line: operating profit fell 9% on DKK 8.7 billion of impairments, US sales rose just 1% on a temporary Medicare bridge, and 2027 leans on a CagriSema FDA decision due before year-end. ## Sources 1. [Yahoo Finance / GuruFocus, Novo Nordisk (NVO) Q3 2026 Earnings Call Highlights, 4 November 2026](https://finance.yahoo.com/healthcare/articles/novo-nordisk-nvo-q3-2026-190719869.html) 2. [Indian Pharma Post, Novo Nordisk raises 2026 outlook after stronger-than-expected Q3, 5 November 2026](https://www.indianpharmapost.com/news/novo-nordisk-raises-2026-outlook-after-stronger-than-expected-q3-driven-by-obesity-drug-sales-22330) 3. [Fierce Biotech, Novo's CEO still looking for deals to 'close some of the gaps,' as misfires hit profits, 5 November 2026](https://www.fiercebiotech.com/biotech/novos-ceo-still-looking-deals-close-some-gaps-misfires-hit-profits) 4. [Yahoo Finance / CFO Dive, Novo hires new CFO as Wegovy pill hits more markets, 4 November 2026](https://finance.yahoo.com/healthcare/articles/novo-hires-cfo-wegovy-pill-191832757.html) 5. [BioSpace, Novo, Lilly battle for oral GLP-1 dominance with data tit for tat, 5 November 2026](https://www.biospace.com/business/novo-lilly-battle-for-oral-glp-1-dominance-with-data-tit-for-tat) --- Novo Nordisk's 27% profit jump is the adjusted number; the reported number fell 9% — The Inference. Canonical: https://theinference.org/article/novo-nordisk-s-27-profit-jump-is-the-adjusted-number-the-reported-number-fell-9